11 completed, 3 unknown, 2 recruiting, 1 withdrawn. 17 Phase 2, 4 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 11, Unknown 3, Recruiting 2, Withdrawn 1 |
| Phase 3 | 4 | Completed 3, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow SARS CoV 2 Infection: new trials by email Literature Review of SARS CoV 2 Infection trials Research Report on SARS CoV 2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS To Measure levels of circulating monocyte/ T cell doublets at Baseline, To measure levels of circulating monocyte/ T cell doublets after 28 days of 2 HOBA treatment, To measure levels of circulating monocyte/ T cell doublets after 28 days of Placebo treatment - Post-Acute COVID-19 Syndrome, Postural Tachycardia Syndrome (POTS) | Phase 2 | Recruiting | Vanderbilt University Medical Center | 50 | 2025-12-18 | 2026-01-22 |
| Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients Remdesivir (RDV) - COVID - 19, Renal Transplant | Phase 2 | Recruiting | Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia | 15 | 2025-09-01 | 2025-09-29 |
| Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 IMNN-101 - SARS CoV 2 Infection | Phase 1 / Phase 2 | Completed | Imunon | 24 | 2024-06-04 | 2025-07-23 |
| Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) in Healthy Pregnant Women TURKOVAC - COVID-19, SARS CoV 2 Infection | Phase 2 | Withdrawn | Health Institutes of Turkey | 2024-01-01 | 2025-05-30 | |
| A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 BIMERVAX, SIIV - SARS CoV 2 Infection, Influenza, Human | Phase 2 | Completed | Hipra Scientific, S.L.U | 279 | 2023-09-04 | 2026-11-17 |
| To Evaluate the Safety, Efficacy,and Pharmacokinetics of Orally Administered Prolectin-M Prolectin-M - COVID-19, SARS CoV 2 Infection | Phase 2 | Unknown | Bioxytran Inc. | 40 | 2023-09-01 | 2023-09-28 |
| Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age. BIMERVAX - SARS CoV 2 Infection | Phase 2 | Completed | Hipra Scientific, S.L.U | 242 | 2023-06-08 | 2026-11-17 |
| Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo - COVID-19 Pandemic, Immunogenicity | Phase 2 | Completed | Sheba Medical Center | 179 | 2022-09-05 | 2024-02-21 |
| Evaluation of the Immunogenicity and Safety of Ad26.COV2.S's COVID-19 Vaccine Ad26.COV2.S - COVID-19, Vaccine Reaction | Phase 2 | Unknown | ANRS, Emerging Infectious Diseases | 200 | 2022-06-02 | 2024-03-27 |
| Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine - COVID -19, SARS CoV 2 Infection | Phase 2 | Completed | Victoria Biomedical Research Institute | 1919 | 2022-05-18 | 2026-02-13 |
| Inhibition of Bradykinin in COVID-19 Infection With Icatibant Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Belfast Health and Social Care Trust | 32 | 2022-05-16 | 2023-09-07 |
| A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. PHH-1V - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Hipra Scientific, S.L.U | 240 | 2022-05-12 | 2026-11-17 |
| A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals Sotrovimab - SARS CoV 2 Infection | Phase 2 | Completed | Sophia Koo, M.D. | 93 | 2022-02-07 | 2024-08-15 |
| Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence Recombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo - SARS CoV 2 Infection | Phase 2 | Completed | Laboratorio Avi-Mex, S.A. de C.V. | 158 | 2021-11-23 | 2025-10-02 |
| Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40 - Covid19, SARS CoV 2 Infection | Phase 1 / Phase 2 | Completed | Laboratorios Hipra, S.A. | 30 | 2021-08-16 | 2023-03-01 |
| PROSPECTIVE OPEN LABEL CLINICAL TRIAL TO ADMINISTER A BOOSTER DOSE OF PFIZER/BIONTECH OR MODERNA COVID-19 VACCINE IN HIGH-RISK INDIVIDUALS Pfizer/BioNTech (BNT162b2), Moderna - SARS CoV 2 Infection, COVID-19 | Phase 2 / Phase 3 | Unknown | DHR Health Institute for Research and Development | 1000 | 2021-07-30 | 2022-03-29 |
| Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. Raloxifene, Placebo - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Dompé Farmaceutici S.p.A | 61 | 2021-01-22 | 2023-12-26 |
COVID-19 (17) · Influenza, Human (1) · Pneumonia (1) · Post-Acute COVID-19 Syndrome (1) · Postural Orthostatic Tachycardia Syndrome (1)
Coronaviridae Infections (17) · Coronavirus Infections (17) · Infections (17) · Lung Diseases (17) · Nidovirales Infections (17) · Pneumonia, Viral (17) · RNA Virus Infections (17) · Respiratory Tract Diseases (17) · Respiratory Tract Infections (17) · Virus Diseases (17) · Pneumonia (16) · Autonomic Nervous System Diseases (1) · Chronic Disease (1) · Disease Attributes (1) · Nervous System Diseases (1)
2019-nCoV Vaccine mRNA-1273 (2) · BNT162 Vaccine (2) · Ad26COVS1 (1) · HIPRA COVID-19 vaccine (1) · KPNA1 protein, human (1) · Raloxifene Hydrochloride (1) · Sodium Chloride (1) · TURKOVAC (1) · galactomannan (1) · icatibant (1) · mRNA-1273.214 COVID-19 vaccine (1) · remdesivir (1) · sinovac COVID-19 vaccine (1) · sotrovimab (1)
Hipra Scientific, S.L.U (3) · ANRS, Emerging Infectious Diseases (1) · Belfast Health and Social Care Trust (1) · Bioxytran Inc. (1) · DHR Health Institute for Research and Development (1) · Dompé Farmaceutici S.p.A (1) · Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia (1) · Health Institutes of Turkey (1) · Imunon (1) · Laboratorio Avi-Mex, S.A. de C.V. (1) · Laboratorios Hipra, S.A. (1) · Sheba Medical Center (1) · Sophia Koo, M.D. (1) · Vanderbilt University Medical Center (1) · Victoria Biomedical Research Institute (1)
Spain (6) · United States (4) · Turkey (Türkiye) (2) · France (1) · Israel (1) · Italy (1) · Kenya (1) · Mali (1) · Mexico (1) · United Kingdom (1)
Teresa Prat (3) · Cyndya Shibao, M.D (1) · Douglas Faller, MD (1) · Elia Torroella (1) · Francesco Sergio, MD, PhD (1) · Gili Regev-Yochay, MD (1) · Jennifer Manne-Goehler, MD, ScD (1) · Joe Kidney, MD (1) · Laura Castro, MD (1) · Niels Hansen, MD (1) · Odile Launay (1) · Samba Sow (1) · Sarah P Hammond, MD (1) · Sohail Rao, MD,MA,DPhil (1) · Sophia Koo, MD (1)
PMID 35582123, PMID 36435633, PMID 37328890, PMID 37775521, PMID 38035747, PMID 38806352, PMID 39527880